financetom
Business
financetom
/
Business
/
BRIEF-Maurel & Prom To Buy 40% Operating Working Interest In Sinu-9 Gas Licence In Colombia
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BRIEF-Maurel & Prom To Buy 40% Operating Working Interest In Sinu-9 Gas Licence In Colombia
Feb 9, 2025 11:19 PM

Feb 10 (Reuters) - Etablissements Maurel et Prom SA

:

* SIGNING OF THE DEFINITIVE AGREEMENT FOR THE ACQUISITION OF

A 40%

OPERATING WORKING INTEREST IN THE SINU-9 GAS LICENCE IN COLOMBIA

* TRANSACTION EFFECTIVE DATE 1 FEBRUARY 2025, CONSIDERATION

$150

MILLION

* M&P TO PAY $20 MILLION DEPOSIT, REMAINDER AT COMPLETION

* M&P HAS 12-MONTH OPTION TO ACQUIRE ADDITIONAL 5% INTEREST

FOR

$18.75 MILLION

Source text:

Further company coverage:

(Gdansk Newsroom)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
TE Connectivity to acquire Richards Manufacturing for about $2.3 billion
TE Connectivity to acquire Richards Manufacturing for about $2.3 billion
Feb 12, 2025
Feb 12 (Reuters) - TE Connectivity ( TEL ) said on Wednesday it would buy Richards Manufacturing Co from funds managed by Oaktree Capital Management and members of the Bier family for about $2.3 billion in cash, aiming to expand in the energy market. ...
CVS Health Q4 Adjusted Earnings Decline, Revenue Increases; 2025 Adjusted EPS Outlook Issued
CVS Health Q4 Adjusted Earnings Decline, Revenue Increases; 2025 Adjusted EPS Outlook Issued
Feb 12, 2025
06:48 AM EST, 02/12/2025 (MT Newswires) -- CVS Health ( CVS ) reported Q4 adjusted earnings Wednesday of $1.19 per diluted share, down from $2.12 a year earlier. Analysts polled by FactSet expected $0.91. Revenue for the quarter ended Dec. 31 was $97.71 billion, up from $93.81 billion a year earlier. Analysts surveyed by FactSet expected $97.09 billion. For 2025,...
Biogen expects lower 2025 profit as multiple sclerosis drugs face fierce competition
Biogen expects lower 2025 profit as multiple sclerosis drugs face fierce competition
Feb 12, 2025
(Reuters) -Biogen forecast 2025 profit below last year's levels and Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for its drugs to treat multiple sclerosis. Its shares fell 3.7% in premarket trading after losing more than 40% of their value last year. The company had a market capitalization of about $20 billion as of its...
NiSource Q4 Adjusted Earnings Fall; Raises 2025 Adjusted Earnings Guidance
NiSource Q4 Adjusted Earnings Fall; Raises 2025 Adjusted Earnings Guidance
Feb 12, 2025
06:54 AM EST, 02/12/2025 (MT Newswires) -- NiSource ( NI ) reported Q4 adjusted earnings Wednesday of $0.49 per diluted share, down from $0.53 a year earlier. Analysts polled by FactSet expected $0.48. The company raised its 2025 adjusted EPS guidance to $1.85 to $1.89 from $1.84 to $1.88. Analysts surveyed by FactSet expect $1.86. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved